Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood. Cell senescence and senescence-associated secretory phenotyp...

Full description

Bibliographic Details
Main Authors: Jianyu Peng, Zijun Lin, Weichun Chen, Jie Ruan, Fan Deng, Lin Yao, Minla Rao, Xingdong Xiong, Shun Xu, Xiangning Zhang, Xinguang Liu, Xuerong Sun
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:Heliyon
Subjects:
Melanoma
Resistance
Vemurafenib
Cell senescence
Cytokines
BRAF inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023049228

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023049228

Similar Items